In 2014, BEUTE [5] described a series of eight patients with status asthmaticus refractory to standard treatment in whom enoximone, a phosphodiesterase (PDE)-3 inhibitor, caused immediate bronchodilatation. To the best of our knowledge, these observations have not yet been confirmed by others. We here report a case of a patient with refractory status asthmaticus who showed rapid and sustained bronchodilation after intravenous administration of enoximone.
A 54-year-old female patient was transferred to our intensive care unit from another hospital with refractory status asthmaticus. The otherwise healthy patient had been diagnosed with mild allergic bronchial asthma for >10 years. Her symptoms were well controlled with formoterol as needed. The patient had been admitted to another hospital 1 day earlier with severe asthma symptoms refractory to treatment with high-dose systematic corticosteroids, magnesium, parenteral and inhaled β 2 -agonists, an inhaled muscarinic receptor antagonist, and inhaled adrenaline. Intubation was required but mechanical ventilation proved almost impossible due to severe airflow obstruction. Upon arrival at our centre, arterial blood gas analysis showed a carbon dioxide tension of 144 mmHg and severe acidosis with a pH of 6.9 (minute ventilation volume of 1 L with a peak inspiratory pressure (P insp ) of 43 cmH 2 O, a positive end-expiratory pressure (PEEP) of 8 cmH 2 O and an inspiratory oxygen fraction (F IO 2 ) of 100%). Venovenous ECMO was instituted immediately, which allowed for effective decarboxylation and protective ventilation ( pressure controlled, F IO 2 40%, P insp 27 cmH 2 O, PEEP 11 cmH 2 O and respiratory rate 11 per min). The patient was sedated with isoflurane, ketamine and propofol. Antiobstructive treatment was continued with systemic corticosteroids, inhaled β 2 -agonists and antimuscarinergic agents.
Over the next 3 days, the clinical situation was stable but severe airflow obstruction persisted, so we decided to try enoximone based on the aforementioned case series [5] . As this compound is no longer readily available, it took 24 h to deliver, during which time the patient's airflow obstruction had slightly improved but continued to be severe (figure 1). Enoximone was administered intravenously starting with a bolus infusion of 0.5 mg·kg −1 over 20 min followed by a constant infusion rate of 5 µg·kg −1 ·min −1 , based on the prescribing information and the previous experience reported by BEUTE [5] . Within 15 min after start of treatment, expiratory flow improved and the tidal volume increased from 470 to 561 mL (figure 1). P insp was gradually decreased from 16 to 10 cmH 2 O over the next 10 h. Besides an increase in heart rate by ∼10 beats per min, no discernible side-effects were observed. Over the next 3 days, airflow obstruction resolved (figure 1) and enoximone was gradually weaned off over a period of 12 h. The ECMO was removed on the third day after enoximone was started and the patient was extubated a few hours later on the same day. Another 3 days later, the patient was transferred to a normal ward.
Enoximone was originally developed for the treatment of severe heart failure [6] . Because of its relatively short plasma half-life of ∼60 min, the drug is usually administered via continuous parenteral infusion [7] . Enoximone acts as an inotrope by inhibiting PDE-3 activity and increasing intracellular cAMP @ERSpublications In a patient with severe status asthmaticus, enoximone, a phosphodiesterase-3 inhibitor, caused immediate bronchodilation http://bit.ly/38UYpUn
